Park Square has placed William Hodder as Chief Executive Officer at NFlection Therapeutics, Inc.
NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that it has appointed William Hodder as CEO.
